Table 4.

Incidence of reported cardiac adverse events (grades ≥3) in black and white patients treated with trastuzumab

Adverse event, n (%)	Black patients (n = 119)	White patients (n = 746)
Any	13 (10.9)	59 (7.9)
Angina pectoris	0 (0.0)	2 (0.3)
Atrial arrhythmia	1 (0.8)	4 (0.5)
Cardiac disorder (NOS)	2 (1.7)	11 (1.5)
Congestive heart failure	5 (4.2)	12 (1.6)
Left ventricular dysfunction	3 (2.5)	22 (2.9)
Myocardial infarction	2 (1.7)	2 (0.3)
Pericardial effusion	0 (0.0)	5 (0.7)
Ventricular arrhythmia	0 (0.0)	1 (0.1)

NOS not otherwise specified